119-HR-5791 Investigative Journalist Impact Analysis

Summary (Document 119-HR-5791)

What it does: Directs FDA to stand up an expedited process to approve supplemental BLAs within 30 days for adding apheresis collection devices at locations not previously licensed—limited to owners/operators that already hold qualifying licenses or accreditation—unless FDA finds site‑specific safety concerns or systemic compliance failures. This overlays existing post‑approval change controls under 21 CFR 601.12. [1]WisPolitics — U.S. Reps. Wied, Schrier: Introduce bipartisan BLOOD Centers Act[2]Legal Information Institute (Cornell Law) — 21 CFR § 601.12 - Changes to an app…

• Intended policy lever: accelerate fixed‑site capacity for platelet/plasma/apheresis collections without re‑proving already‑licensed SOPs or equipment classes, while preserving FDA stop‑gaps for safety/purity/potency and for firms with systemic lapses. [1]WisPolitics — U.S. Reps. Wied, Schrier: Introduce bipartisan BLOOD Centers Act
• Context: the U.S. blood system experiences recurring, seasonally driven shortages; 2023–2024 episodes saw materially reduced inventories and canceled drives. [3]American Red Cross — Red Cross: Emergency Blood Shortage May Delay Medical Proc…[4]American Red Cross — Emergency blood shortage: Red Cross supply drops 25%[5]American Red Cross — Winter weather cancels record-breaking 534 Red Cross blood…

Economic Effects

Signals, capacity, costs, and labor market considerations.

• Supply availability: 2021 NBCUS shows ~11.78 million RBC units collected and ~10.76 million transfused; stabilizing trends still leave thin buffers. Faster licensing of new apheresis sites could help centers match local demand, particularly for platelets (short shelf life). [6]CDC Stacks / Transfusion — Continued stabilization of blood collections and tra…
• Avoided shortage costs: recent emergency shortages forced hospitals to defer procedures; reducing lead time to open fixed sites can curb such disruptions in high‑variance periods (heat waves, storms). [4]American Red Cross — Emergency blood shortage: Red Cross supply drops 25%[7]Web search · turn 2 #0
• Regulatory transaction costs: today, facility/equipment additions are typically “major” or “moderate” manufacturing changes under 21 CFR 601.12 (PAS or CBE). A statutory 30‑day default could compress timelines but shifts workload to FDA; electronic submission programs exist but still require review capacity. [2]Legal Information Institute (Cornell Law) — 21 CFR § 601.12 - Changes to an app…[8]FDA — Availability of FDA’s eSubmitter Program for Regulatory Submissions from…
• Labor constraints: scaling fixed sites requires phlebotomists and lab staff. BLS projects ~6% growth for phlebotomists (2024–2034) with ~18,400 annual openings, a potential bottleneck if expansion outruns hiring. [9]U.S. Bureau of Labor Statistics — Phlebotomists – Occupational Outlook Handbook
• Market structure: if “blood center” is interpreted to include source‑plasma facilities, faster site additions could advantage for‑profit plasma operators in some regions, affecting wages and donor flows; scope will ultimately depend on FDA implementation and definitions cross‑referencing blood/component vs source plasma programs. (Risk flagged; outcome uncertain.) [10]FDA — Changes to an Approved Application: Biological Products: Human Blood and…

Social Effects

• Access: more fixed donation points can reduce travel/time barriers for donors and potentially improve supply to community hospitals, mitigating cancellations and care delays during adverse weather or seasonal lulls. [7]Web search · turn 2 #0[11]Web search · turn 2 #2
• Safety expectations: FDA retains authority to deny expedited approvals where site‑specific risks or systemic failures exist; bacterial contamination of platelets remains a salient hazard, with FDA guidance outlining control strategies and reporting pathways for changes under 601.12. [12]FDA — Bacterial Risk Control Strategies for Blood Collection Establishments and…[2]Legal Information Institute (Cornell Law) — 21 CFR § 601.12 - Changes to an app…
• Equity lens: federal advisors have highlighted resilience and data‑sharing gaps across the blood/tissue ecosystem; strengthening capacity without parallel quality and biovigilance improvements risks uneven benefits across regions and patient groups. [13]Web search · turn 4 #1[14]Web search · turn 4 #2

Environmental Effects

Two countervailing forces: more devices and disposables vs. potentially fewer donor miles.

• Device/waste footprint: U.S. health care is ~8–10% of national GHG emissions; scaling single‑use apheresis kits and associated logistics adds marginal waste and upstream emissions unless offset by procurement/processing changes. [15]Health Affairs (via PubMed) — Health Care Pollution And Public Health Damage In…
• Sterilization externalities: many medical devices are sterilized with ethylene oxide (EtO). EPA’s 2024 NESHAP amendments require ~90% emission reductions at nearly 90 commercial sterilizers, mitigating community cancer risk from any sterilization throughput increase. [16]U.S. EPA — Final Amendments to Strengthen Air Toxics Standards for Ethylene Oxi…[17]U.S. EPA — EPA announces final rule to slash toxic emissions of ethylene oxide…
• Donor travel: decentralizing collection sites can lower travel‑related emissions if donors/volunteers go shorter distances; patient/donor travel is a non‑trivial slice of U.S. health‑care emissions. [18]JAMA Network Open — Carbon Emissions From Patient Travel for Health Care

Temporal Analysis

• Near term (0–2 years): If enacted, FDA must stand up the pathway within 180 days and meet 30‑day clocks; centers with qualifying licensure/accreditation could add devices/sites faster, marginally easing platelet constraints in peak seasons. Oversight load on CBER review/inspection staff rises immediately. [1]WisPolitics — U.S. Reps. Wied, Schrier: Introduce bipartisan BLOOD Centers Act
• Medium term (2–5 years): Network effects—more fixed sites in metro/rural gaps—could stabilize inventories seen in NBCUS data, provided donor recruitment keeps pace and staff are available. [6]CDC Stacks / Transfusion — Continued stabilization of blood collections and tra…[9]U.S. Bureau of Labor Statistics — Phlebotomists – Occupational Outlook Handbook
• Long term (5+ years): System risk shifts from licensing queues to continuous quality management (SOP drift, training, IT/cyber resilience) across a larger site footprint; benefits become contingent on sustained compliance and data reporting. [19]FDA — Important Information for Blood Establishments Regarding Cybersecurity Re…

Unintended Consequences (Risks to Monitor)

Assessment (Analytical Stance)

On balance, likely impact is neutral.

If FDA resources, guidance, and inspection capacity scale with the 30‑day mandate, the policy should modestly improve availability and geographic access without materially elevating safety risk; if not, the risk profile tilts toward compliance gaps and uneven quality. Given current evidence and safeguards retained in the bill text, the expected net effect is neutral. [1]WisPolitics — U.S. Reps. Wied, Schrier: Introduce bipartisan BLOOD Centers Act[2]Legal Information Institute (Cornell Law) — 21 CFR § 601.12 - Changes to an app…

Key Metrics

Sources: NBCUS 2021; EPA final EtO NESHAP (2024); Health‑sector emissions estimate; American Red Cross (Aug. 2024); BLS OOH (2024). [6]CDC Stacks / Transfusion — Continued stabilization of blood collections and tra…[16]U.S. EPA — Final Amendments to Strengthen Air Toxics Standards for Ethylene Oxi…[15]Health Affairs (via PubMed) — Health Care Pollution And Public Health Damage In…[4]American Red Cross — Emergency blood shortage: Red Cross supply drops 25%[9]U.S. Bureau of Labor Statistics — Phlebotomists – Occupational Outlook Handbook

Sourcing and Method Notes

- Statute/bill status and scope from primary text and official statements; regulatory baselines from CFR and FDA guidance. Blood system context from HHS/CDC NBCUS and public shortage alerts. Environmental context from EPA final rules and peer‑reviewed estimates of health‑sector emissions and travel. Where outcomes depend on implementation (e.g., definition of eligible centers), we flagged uncertainty rather than infer. [1]WisPolitics — U.S. Reps. Wied, Schrier: Introduce bipartisan BLOOD Centers Act[2]Legal Information Institute (Cornell Law) — 21 CFR § 601.12 - Changes to an app…[22]HHS (OIDP) — National Blood Collection & Utilization Survey (NBCUS)[6]CDC Stacks / Transfusion — Continued stabilization of blood collections and tra…[16]U.S. EPA — Final Amendments to Strengthen Air Toxics Standards for Ethylene Oxi…[15]Health Affairs (via PubMed) — Health Care Pollution And Public Health Damage In…